Granules India has reported results for July–September, the second quarter of 2026–27. Chairman and Managing Director Krishna Prasad Chigurupati said quarterly revenue crossed ₹1,500 crore despite higher input and freight costs linked to tensions in West Asia.
Key numbers (year on year)
- Revenue: ₹1,297 crore to ₹1,560 crore (+20%)
- Net profit: ₹130.6 crore to ₹181.8 crore (+39%)
- EBITDA: ₹278.2 crore to ₹337.6 crore (+21%); margin 21.6%
- Profit before tax: ₹175.9 crore to ₹243.4 crore (+38%)
- Net cash of ₹828 crore, against net debt of ₹101.2 crore a quarter earlier
North America brought in 72% of revenue and Europe 16%. By segment, finished dosages were 73%, APIs 13% and peptide CDMO 3%.
What management said
On the earnings call, management said a USFDA inspection at the Gagillapur plant produced 11 observations, all of which it considers addressable, with a reply due in 15 business days. It plans five US launches over the next two quarters, expects Genome Valley utilisation to rise from about 25% to over 50% by the fourth quarter, and plans about ₹2,000 crore of growth capex over three to four years.
